PF-07321332

PF-07321332 Uses, Dosage, Side Effects, Food Interaction and all others data.

PF-07321332, by Pfizer, is an orally bioavailable 3C-like protease (3CLPRO) inhibitor that is the subject of clinical trial NCT04756531. This drug is being investigated for safety, tolerability, and pharmacokinetics before moving on to studies of efficacy in the treatment or prophylaxis of COVID-19. 3CL PRO Without the activity of the SARS-CoV-2 3CL PRO

In 2020, Pfizer was investigating another potential treatment for SARS-CoV-2, PF-07304814. Both drugs were inhibitors of SARS-CoV-2 3CL PRO If successful, PF-07321332 can be prescribed to patients before they require hospitalization, while PF-07304814 requires intravenous administration in hospital.

Table Of contents

• PF-07321332
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	PF-07321332
Generic	PF-07321332
Type
Formula	C23H32F3N5O4
Weight	Average: 499.535 Monoisotopic: 499.240639019
Groups	Investigational
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

PF-07321332 is an oral protease inhibitor in clinical trials for the treatment of SARS-CoV-2 infections.

PF-07321332 is currently undergoing clinical trials for safety and efficacy in the treatment and prevention of COVID-19.

How PF-07321332 works

PF-07321332 is an inhibitor of a cysteine residue in the 3C-like protease (3CL^PRO) of SARS-CoV-2. This cysteine is responsible to the activity of the 3CL^{PRO The 3CLPRO These polyproteins contain the 3CLPRO Without the activity of the 3CLPRO}

Innovators Monograph

You find simplified version here PF-07321332